19,736 Shares in ABIVAX Société Anonyme (NASDAQ:ABVX) Purchased by Two Sigma Investments LP

Two Sigma Investments LP bought a new stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 19,736 shares of the company’s stock, valued at approximately $144,000.

A number of other large investors also recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC grew its holdings in ABIVAX Société Anonyme by 190.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock valued at $11,078,000 after buying an additional 991,781 shares in the last quarter. Franklin Resources Inc. increased its holdings in ABIVAX Société Anonyme by 10.7% in the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after acquiring an additional 141,710 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in ABIVAX Société Anonyme by 45.7% in the 4th quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock worth $10,512,000 after purchasing an additional 450,413 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of ABIVAX Société Anonyme by 44.2% during the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after purchasing an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of ABIVAX Société Anonyme by 83.5% during the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after purchasing an additional 389,247 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABVX has been the topic of a number of research analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ:ABVX opened at $7.02 on Friday. The firm has a fifty day simple moving average of $6.50 and a two-hundred day simple moving average of $6.86. ABIVAX Société Anonyme has a 52 week low of $4.77 and a 52 week high of $14.22.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.